📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-09-26 20:57
0 analysed today
FollowTelegram
0
Today
149,939
All-time analysed
42,983
Positive
6,669
Negative
91,579
Neutral
8,640
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
3 announcements match the current filters (relevance ≥ 5).
Bandaram Pharma Packtech Boards to Consider Scheme of Amalgamation on Sept 30, 2026
Bandaram Pharma Packtech has scheduled a board meeting for September 30, 2026, to consider a proposed scheme of arrangement or amalgamation. The micro-cap healthcare service provider currently has a market capitalization of Rs 83 Cr and generated TTM revenue of Rs 79 Cr. In line with insider trading regulations, the trading window for dealing in company securities is closed from September 27, 2026, until 48 hours post-declaration of the outcome. Details regarding the merging entities, swap ratio, and deal size have not yet been disclosed.
Confidence: MEDIUM
What changedThe board has convened to formally review and potentially approve a proposal for a scheme of arrangement or amalgamation.
Why it mattersA corporate restructuring or amalgamation could significantly shift the business scale, asset base, or equity dilution for this Rs 83 Cr market cap company.
Board meeting date: 30.09.2026Trading window closure start: 27.09.2026Current Market Cap: Rs 83 CrTTM Revenue: Rs 79 Cr
📅 Short termMarket focus will remain on the detailed outcome release following the September 30 meeting to assess valuation and swap ratio impacts.
📈 Long termDepending on the structure of the amalgamation, it could expand operational scale or significantly alter share capital and promoter holding.
⚠ Risk flags
- Potential equity dilution depending on the swap ratio
- Lack of details on whether the transaction involves related parties or external entities
- Lengthy regulatory and NCLT approval timelines typical of amalgamation schemes
Key Highlights
Board meeting scheduled for September 30, 2026, to evaluate a Scheme of Arrangement/Amalgamation
Trading window closed starting September 27, 2026, reopening 48 hours after board decision
Target or merging entities and financial terms are currently not disclosed
Company trades at Rs 20.2 with an Rs 83 Cr market capitalization as of the announcement
👀 What to Watch
Track the board meeting outcome on September 30, 2026, specifically looking for the merging entities, share swap ratios, dilution impact, and regulatory approval pathways.
Bandaram Pharma Q1 FY27 Consolidated Revenue up 195% YoY to ₹23.95 Cr; PAT at ₹0.68 Cr
Bandaram Pharma Packtech reported a strong consolidated performance for Q1 FY27, with revenue jumping to ₹23.95 Cr from ₹8.10 Cr in the same quarter last year. Consolidated net profit rose significantly to ₹0.68 Cr compared to a marginal ₹0.02 Cr YoY. This growth is primarily driven by its 55% subsidiary, VSR Paper and Packaging Limited, which contributed ₹22.42 Cr to the top line. However, the standalone pharma business remains under pressure, reporting a net loss of ₹0.35 Cr on revenue of ₹2.98 Cr.
Confidence: HIGH
What changedThe company reported its Q1 FY27 financial results showing a massive scale-up in consolidated operations and confirmed the re-appointment of its statutory auditors and an independent director.
Why it mattersThe results highlight that the company's value is now heavily tied to its packaging subsidiary rather than its standalone pharma operations, which represents a significant shift in the business profile.
Consolidated Revenue (Q1 FY27): ₹23.95 CrConsolidated PAT (Q1 FY27): ₹0.68 CrQ1 Revenue vs TTM Revenue: ~38%Standalone Net Loss (Q1 FY27): ₹0.35 CrAGM Date: 18.09.2026
📅 Short termThe sharp jump in consolidated revenue and profit is likely to be viewed positively by the market in the coming days.
📈 Long termThe long-term outlook depends on the company's ability to integrate its packaging acquisitions effectively and whether the standalone pharma unit can reach break-even.
⚠ Risk flags
- Loss-making standalone operations
- High reliance on a single subsidiary (VSR Paper) for consolidated profits
- High P/E ratio of 94.8 indicates expensive valuation relative to current earnings
Key Highlights
Consolidated revenue for Q1 FY27 reached ₹23.95 Cr, a 195% increase over Q1 FY26 (₹8.10 Cr).
Consolidated PAT grew to ₹68.44 lakhs from ₹2.47 lakhs in the year-ago period.
Subsidiary VSR Paper and Packaging Limited (55% stake) contributed ₹22.42 Cr in revenue and ₹1.01 Cr in profit.
Standalone operations reported a net loss of ₹35.68 lakhs despite revenue growing to ₹2.98 Cr from ₹0.75 Cr YoY.
Board approved re-appointment of Independent Director Suryaprakasa Rao Bommisetti for a 5-year term starting March 2027.
👀 What to Watch
Investors should monitor the sustainability of margins in the packaging subsidiary (VSR Paper) and watch for any turnaround signs in the standalone pharma business, which is currently loss-making.
Bandaram Pharma Q1 FY27 Consolidated PAT Jumps to ₹0.68 Cr from ₹0.02 Cr YoY
Bandaram Pharma Packtech reported a significant turnaround in consolidated performance for Q1 FY27, with revenue reaching ₹23.95 Cr, a 195% increase compared to ₹8.10 Cr in Q1 FY26. Consolidated Net Profit rose to ₹0.68 Cr from just ₹0.02 Cr in the year-ago period. However, the standalone business remains under pressure, reporting a loss of ₹0.36 Cr on revenue of ₹2.98 Cr. The overall growth is heavily reliant on its 55% subsidiary, VSR Paper and Packaging Limited, which contributes the majority of the group's top and bottom lines.
Confidence: HIGH
What changedThe company has transitioned from near-break-even to meaningful consolidated profitability, driven by its packaging subsidiary.
Why it mattersThe results highlight a significant divergence between the loss-making standalone entity and the profitable consolidated group, making the subsidiary's performance critical for valuation.
Consolidated Revenue (Q1 FY27): ₹23.95 CrConsolidated PAT (Q1 FY27): ₹0.68 CrStandalone Net Loss: ₹0.36 CrQ1 Revenue vs TTM Revenue: ~38%Consolidated EPS: ₹0.11
📅 Short termThe sharp jump in consolidated profit and revenue is likely to be viewed positively by the market in the short term, despite standalone weakness.
📈 Long termThe long-term outlook depends on the company's ability to scale its packaging business and resolve the persistent losses in its standalone operations.
⚠ Risk flags
- Loss-making standalone operations
- High dependence on a 55%-owned subsidiary
- High P/E ratio of 94.8 relative to small PAT
Key Highlights
Consolidated Revenue from operations grew 195% YoY to ₹23.95 Cr
Consolidated Net Profit increased to ₹68.44 lakhs compared to ₹2.47 lakhs in Q1 FY26
Standalone operations reported a net loss of ₹35.68 lakhs for the quarter
Consolidated EPS improved to ₹0.11 from ₹0.02 YoY
VSR Paper and Packaging Limited (55% subsidiary) remains the primary revenue driver
👀 What to Watch
Investors should monitor the margin sustainability of the packaging subsidiary and watch for any turnaround signs in the standalone pharma packtech business during the upcoming AGM on September 18, 2026.
